Direct oHSV Infection Induces DC Maturation and a Tumor Therapeutic Response
Viruses · 2025
DOI: 10.3390/v17081134 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Doyeon Kim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Childhood Cancer Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH 43205, USA. Hauptthemen laut MEDLINE: Dendritic Cells, Oncolytic Virotherapy, Oncolytic Viruses, Glioma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, CancerFree KIDS, Cancer Free KIDS.
Abstract (Originalsprache)
Oncolytic herpes simplex virus (oHSV) is a promising cancer immunotherapy that induces tumor cell lysis and stimulates anti-tumor immunity. Our previous single-cell RNA sequencing analysis of oHSV-treated medulloblastoma tumors revealed expansion and activation of tumor-infiltrating dendritic cells (DCs), and direct oHSV infection of DCs within the brain. While the therapeutic effects of oHSVs have been primarily attributed to tumor cell infection, we hypothesize that direct infection of DCs also contributes to therapeutic efficacy by promoting DC maturation and immune activation. Although the oHSV infection in DCs was abortive, it led to increased expression of major histocompatibility complex (MHC) class I/II and co-stimulatory molecules. oHSV-infected DCs activated naïve CD4+ and CD8+ T cells, inducing expression of CD69 and CD25. These primed T cells exhibited enhanced cytotoxicity against CT-2A glioma cells. Adoptive transfer of oHSV-infected DCs via subcutaneous injection near inguinal lymph nodes delayed tumor growth in a syngeneic CT-2A glioma model, independent of tumor viral replication and lysis. Mechanistically, our in vitro studies demonstrate that oHSV can directly infect and functionally activate DCs, enabling them to prime effective anti-tumor T cell responses. This study highlights the anti-tumor potential of leveraging oHSV-infected DCs to augment viroimmunotherapy as a cancer therapeutic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Childhood Cancer Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH 43205, USA.
- College of Medicine, The Ohio State University, Columbus, OH 43220, USA.
- Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH 43220, USA.
- Department of Pediatrics, Division of Pediatric Infectious Diseases, Nationwide Children's Hospital, Columbus, OH 43205, USA.
ORCID-Profile: Doyeon Kim, Jack Hedberg, Alexia K Martin, Ilse Hernandez-Aguirre, Yeaseul Kim, Ravi Dhital, Kevin A Cassady
Förderung
- NCI NIH HHS
- CancerFree KIDS
- Cancer Free KIDS
- Department of Defense
- NIH
Zitieren
APA
Kim, D., Kelly, M., Hedberg, J., Martin, A. K., Hernandez-Aguirre, I., Kim, Y., Cain, L. R., Dhital, R., & Cassady, K. A. (2025). Direct oHSV Infection Induces DC Maturation and a Tumor Therapeutic Response. Viruses. https://doi.org/10.3390/v17081134
Vancouver
Kim D, Kelly M, Hedberg J, Martin AK, Hernandez-Aguirre I, Kim Y, et al. Direct oHSV Infection Induces DC Maturation and a Tumor Therapeutic Response. Viruses. 2025. doi:10.3390/v17081134
BibTeX
@article{Kim2025,
author = {Kim, Doyeon and Kelly, Michael and Hedberg, Jack and Martin, Alexia K and Hernandez-Aguirre, Ilse and Kim, Yeaseul and Cain, Lily R and Dhital, Ravi and Cassady, Kevin A},
title = {Direct oHSV Infection Induces DC Maturation and a Tumor Therapeutic Response},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17081134}
}
EUVIMED